{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:06:51Z","timestamp":1777774011687,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01336-1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:26:42Z","timestamp":1775287602000},"page":"1479-1491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA"],"prefix":"10.1007","volume":"15","author":[{"given":"Eldad A.","family":"Hod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Rank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lipschitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yona","family":"Feit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Baumfeld Andre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"1336_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19). https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023. Accessed 15 Oct 2025."},{"issue":"6","key":"1336_CR2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313661121","volume":"121","author":"E Paglino","year":"2024","unstructured":"Paglino E, Lundberg DJ, Wrigley-Field E, Zhou Z, Wasserman JA, Raquib R, et al. Excess natural-cause mortality in US counties and its association with reported COVID-19 deaths. Proc Natl Acad Sci USA. 2024;121(6):e2313661121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJMp2213920","volume":"388","author":"WM El-Sadr","year":"2023","unstructured":"El-Sadr WM, Vasan A, El-Mohandes A. Facing the new Covid-19 reality. N Engl J Med. 2023;388(5):385\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"e01694","DOI":"10.1128\/JCM.01694-20","volume":"58","author":"P Muench","year":"2020","unstructured":"Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M, et al. Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10):e01694\u2013e1720.","journal-title":"J Clin Microbiol"},{"key":"1336_CR5","unstructured":"Food and Drug Administration. Elecsys Anti SARS-CoV-s instructions for use. https:\/\/www.fda.gov\/media\/137605\/download. Accessed 19 Aug 2025."},{"key":"1336_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2023.113486","volume":"518","author":"A Gaeta","year":"2023","unstructured":"Gaeta A, Angeloni A, Napoli A, Pucci B, Cinti L, Roberto P, et al. Anti-N SARS-CoV-2 assays for evaluation of natural viral infection. J Immunol Methods. 2023;518:113486.","journal-title":"J Immunol Methods"},{"issue":"1","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40121-024-01090-2","volume":"14","author":"Y Jin","year":"2025","unstructured":"Jin Y, Yang F, Rank CM, Letovsky S, Ramge P, Jochum S. SARS-CoV-2 SPIKE antibody levels can indicate immuno-resilience to re-infection: a real-world study. Infect Dis Ther. 2025;14(1):229\u201343.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1473-3099(20)30322-4","volume":"20","author":"AK Winter","year":"2020","unstructured":"Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis. 2020;20(7):758\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1336_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115313","volume":"100","author":"J Tanis","year":"2021","unstructured":"Tanis J, Vancutsem E, Pi\u00e9rard D, Weets I, Bjerke M, Schiettecatte J, et al. Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays. Diagn Microbiol Infect Dis. 2021;100(1):115313.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/jmv.26669","volume":"93","author":"J Favresse","year":"2021","unstructured":"Favresse J, Cadrobbi J, Eucher C, Elsen M, Laffineur K, Dogn\u00e9 JM, et al. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. J Med Virol. 2021;93(4):2262\u20139.","journal-title":"J Med Virol"},{"issue":"8","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/clinchem\/hvaa132","volume":"66","author":"MS Tang","year":"2020","unstructured":"Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical performance of the Roche SARS-CoV-2 serologic assay. Clin Chem. 2020;66(8):1107\u20139.","journal-title":"Clin Chem"},{"issue":"5","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ajcp\/aqaa155","volume":"154","author":"CW Chan","year":"2020","unstructured":"Chan CW, Parker K, Tesic V, Baldwin A, Tang NY, van Wijk XMR, et al. Analytical and clinical evaluation of the automated Elecsys Anti-SARS-CoV-2 antibody assay on the Roche cobas e602 analyzer. Am J Clin Pathol. 2020;154(5):620\u20136.","journal-title":"Am J Clin Pathol"},{"key":"1336_CR13","unstructured":"Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices guidance for industry and Food and Drug Administration staff. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-real-world-evidence-support-regulatory-decision-making-medical-devices. Accessed 19 Aug 2025."},{"issue":"4","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/cpt.3539","volume":"117","author":"E Baumfeld Andre","year":"2025","unstructured":"Baumfeld Andre E, Gee M, Magnus C, Greeman S, White P, de Mars M, et al. The Open Hand Initiative: facilitating the use of real-world evidence in regulatory submissions through collaboration and transparency. Clin Pharmacol Ther. 2025;117(4):1072\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1336_CR15","unstructured":"Centers for Disease Control and Prevention. Symptoms of COVID-19. 2025. https:\/\/www.cdc.gov\/covid\/signs-symptoms\/index.html. Accessed 19 Aug 2025."},{"key":"1336_CR16","unstructured":"World Health Organization. Coronavirus disease (COVID-19). https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_3. Accessed 19 Aug 2025."},{"key":"1336_CR17","unstructured":"R Core Team. R: a language and environment for statistical computing (Version 4.4.1). R Foundation for Statistical Computing; 2024. https:\/\/www.R-project.org\/."},{"key":"1336_CR18","unstructured":"CLSI. Evaluation of qualitative, binary output examination performance 3rd ed. CLSI guideline EP12. Clinical and Laboratory Standards Institute; 2023."},{"key":"1336_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jbi.2014.02.013","volume":"48","author":"K Hajian-Tilaki","year":"2014","unstructured":"Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform. 2014;48:193\u2013204.","journal-title":"J Biomed Inform"},{"issue":"4","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s40121-021-00504-9","volume":"10","author":"E Riester","year":"2021","unstructured":"Riester E, Majchrzak M, M\u00fchlbacher A, Tinguely C, Findeisen P, Hegel JK, et al. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect Dis Ther. 2021;10(4):2381\u201397.","journal-title":"Infect Dis Ther"},{"issue":"12","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/S1473-3099(20)30634-4","volume":"20","author":"National SARS-CoV-2 Serology Assay Evaluation Group","year":"2020","unstructured":"National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390\u2013400.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.pathol.2021.05.093","volume":"53","author":"KA Bond","year":"2021","unstructured":"Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, et al. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology. 2021;53(6):773\u20139.","journal-title":"Pathology"},{"issue":"5","key":"1336_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251587","volume":"16","author":"ML Buchholtz","year":"2021","unstructured":"Buchholtz ML, Arend FM, Eichhorn P, Weigand M, Kleinhempel A, H\u00e4usler K, et al. SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS. PLoS ONE. 2021;16(5):e0251587.","journal-title":"PLoS ONE"},{"issue":"3","key":"1336_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcvp.2021.100030","volume":"1","author":"LJ Donato","year":"2021","unstructured":"Donato LJ, Theel ES, Baumann NA, Bridgeman AR, Blommel JH, Wu Y, et al. Evaluation of the Genalyte Maverick SARS-CoV-2 multi-antigen serology panel. J Clin Virol Plus. 2021;1(3):100030.","journal-title":"J Clin Virol Plus"},{"issue":"10","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/23744235.2021.1931434","volume":"53","author":"O Ekelund","year":"2021","unstructured":"Ekelund O, Ekblom K, Somajo S, Pattison-Granberg J, Olsson K, Petersson A. High-throughput immunoassays for SARS-CoV-2\u2014Considerable differences in performance when comparing three methods. Infect Dis. 2021;53(10):805\u201310.","journal-title":"Infect Dis"},{"issue":"6","key":"1336_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/jalm\/jfaa134","volume":"5","author":"CS Lau","year":"2020","unstructured":"Lau CS, Hoo SP, Yew SF, Ong SK, Lum LT, Heng PY, et al. Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay. J Appl Lab Med. 2020;5(6):1313\u201323.","journal-title":"J Appl Lab Med"},{"issue":"2","key":"1336_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ajcp\/aqaa200","volume":"155","author":"DM Manthei","year":"2021","unstructured":"Manthei DM, Whalen JF, Schroeder LF, Sinay AM, Li SH, Valdez R, et al. Differences in performance characteristics among four high-throughput assays for the detection of antibodies against SARS-CoV-2 using a common set of patient samples. Am J Clin Pathol. 2021;155(2):267\u201379.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1336_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.pathol.2020.09.007","volume":"52","author":"SS Tan","year":"2020","unstructured":"Tan SS, Saw S, Chew KL, Huak CY, Khoo C, Pajarillaga A, et al. Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays. Pathology. 2020;52(7):770\u20137.","journal-title":"Pathology"},{"issue":"1","key":"1336_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-022-01752-y","volume":"19","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto M, Okazaki K, Kitai Y, Shinohara K, Yukawa S, Noguchi T, et al. Comparison of six antibody assays and two combination assays for COVID-19. Virol J. 2022;19(1):24.","journal-title":"Virol J"},{"issue":"2","key":"1336_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279956","volume":"18","author":"CV Rodriguez-Watson","year":"2023","unstructured":"Rodriguez-Watson CV, Louder AM, Kabelac C, Frederick CM, Sheils NE, Eldridge EH, et al. Real-world performance of SARS-Cov-2 serology tests in the United States, 2020. PLoS ONE. 2023;18(2):e0279956.","journal-title":"PLoS ONE"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01336-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:27Z","timestamp":1777484067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01336-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eldad A. Hod, Joseph Lipschitz, Alex J. Rai, Annie Qiu, and Yona Feit have no conflicts to disclose. Baiyu Yang was an employee of Roche Molecular Systems at the time of this study and holds stock in F. Hoffmann-La Roche AG. Christopher M. Rank is an employee of Roche Diagnostics GmbH and holds stock in F. Hoffmann-La Roche Ltd. Carsten Magnus is an employee of and holds stock in F. Hoffmann-La Roche Ltd. Elodie Baumfeld Andre was an employee of Roche Molecular Systems at the time of this study and holds stocks in F. Hoffmann-La Roche AG. Fei Yang was an employee at F. Hoffmann-La Roche Ltd when the work was conducted. He owns stock at F. Hoffmann-La Roche Ltd. He currently works at Philip Morris International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"To ensure adherence to ethical and regulatory standards, the protocol for this study was reviewed and approved by the Columbia University Medical Center Institutional Review Board (IRB-AAAT6416). COBAS and ELECSYS are trademarks of Roche. Any other product names and trademarks are the property of their respective owners. The Elecsys Anti-SARS-CoV-2 immunoassay is approved in the EU for serology\/antibody testing. It has an EUA under Section\u00a0564 of the US Federal Food, Drug, and Cosmetic Act.US and 510(k) clearance (K250768).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}